Review Article

Gastrointestinal Stromal Tumors: Molecular Mechanisms and Targeted Therapies

Erinn Downs-Kelly and Brian P. Rubin

Departments of Anatomic and Molecular Pathology, Cleveland Clinic, 9500 Euclid Avenue, L25, Cleveland, OH 44195, USA

Correspondence should be addressed to Erinn Downs-Kelly, downske@ccf.org

Received 22 December 2010; Accepted 25 January 2011

Academic Editor: Hanlin L. Wang

Copyright © 2011 E. Downs-Kelly and B. P. Rubin. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract and are diverse not only in their clinical behavior but also in their histologic appearance. GISTs are insensitive to conventional sarcoma chemotherapy and radiation. However GISTs are sensitive to small-molecule tyrosine kinase inhibitors as 85–90% of GISTs have KIT or platelet-derived growth factor receptor alpha (PDGFRA) mutations, which drive tumorigenesis. This review will briefly touch on the clinicopathological features of GIST, while the majority of the review will focus on the clinical and treatment ramifications of KIT and PDGFRA mutations found in GIST.

1. Background

The last twenty years have seen great advances in the understanding of gastrointestinal stromal tumors (GISTs), from identifying their typical immunohistochemical phenotype and the molecular alterations that drive these tumors to the knowledge of their biologic potential and the use of effective tyrosine kinase inhibitor targeted therapy. GISTs are the most common mesenchymal neoplasms of the gastrointestinal tract, and although insensitive to conventional sarcoma chemotherapy and radiation, they have shown dramatic clinical response to targeted kinase therapy. Activating mutations in KIT or platelet-derived growth factor receptor alpha (PDGFRA) have been identified in up to 80% and 10% of GISTs, respectively [1–5]. These mutations have been detected in small, GISTs may occur anywhere in the gastrointestinal tract but are most common in the stomach and small bowel (roughly 60% and 30%, resp.), while 10% arise in other parts of the gastrointestinal tract (esophagus, colon, and rectum), and a small percentage are extragastrointestinal, arising in the mesentery, omentum, retroperitoneum, or pelvis [9, 10]. Once thought to represent smooth muscle neoplasms [11–13], GISTs are now known to share features with interstitial cells of Cajal (ICC), based on ultrastructure findings and immunophenotyping [14–19]. ICC are present within the interstitium of the muscularis propria throughout the gastrointestinal tract and serve a pacemaker function by generating and propagating electrical slow waves of depolarization, effectively coordinating peristalsis [16–18, 20, 21]. The current hypothesis is that GISTs arise from either the ICC or from a common progenitor stem cell [22].

GISTs are heterogenous, both from a clinical and morphologic stand point. Clinically, GISTs range from a small incidental finding that is entirely benign to a larger symptomatic neoplasm that may behave aggressively with metastatic potential. Regardless of their clinical diversity, GISTs share common genetic alterations. As mentioned above, mutually exclusive mutations in KIT or PDGFRA have been identified in up to 80% and 10% of GISTs, respectively [1–5]. These mutations have been detected in small,
incidentally identified GISTs, suggesting that they occur as an early event in tumorigenesis [23, 24]. The majority of these mutations are somatic; however, germline mutations have been identified in rare families [25–30]. Approximately 5%–10% of GIST patients will lack mutations in either gene although KIT kinase activation is identified even in the absence of the mutation [2]. More recently, a primary V600E BRAF mutation was found within 7% of adult GIST patients that lacked either KIT or PDGFRA mutations [31]. Morphologically, GISTs may be either spindle cell, epithelioid, or mixed spindle and epithelioid cell types [32]. Epithelioid and mixed cell type GISTs are most commonly encountered in the stomach compared to other gastrointestinal sites [33, 34]. CD117 (KIT), the product of the KIT gene, has been identified as a sensitive immunohistochemical marker of GISTs from all sites and is expressed in up to 95% of GISTs with expression seen in wild-type tumors as well [35]. Approximately 5% of GISTs do not express KIT [36, 37], and this subset of KIT-negative GISTs frequently contain a PDGFRA mutation [3]. Roughly 70% of GISTs will express CD34 [38, 39], 20%–30% are positive for smooth muscle actin, 5% may express some positivity for S100 protein, and 1%–2% are positive for desmin or keratin [14, 32, 35].

2. KIT and PDGFRA

KIT and PDGFRA reside on chromosome 4q12 [40] with both genes encoding homologous transmembrane glycoproteins [41, 42] that are members of a type III tyrosine kinase receptor family. These transmembrane proteins contain an extracellular/ligand binding domain (EC) with five immunoglobulin-like loops that function in ligand binding and dimerization. This EC domain is connected to a cytoplasmic domain by a transmembrane domain. The cytoplasmic domain is composed of a juxtamembrane (JM) domain and tyrosine kinase domain (TK1 and TK2) which contains an adenosine triphosphate binding site and a phosphotransferase region separated by a kinase insert [43]. The JM domain regulates KIT tyrosine kinase activity by inhibiting activity in the absence of KIT ligand [44].

In the normal state, KIT and PDGFRA bind their respective ligands (stem cell factor and platelet-derived growth factors), leading to the phosphorylation of signal transduction proteins that modulate cell proliferation and chemotaxis and inhibit apoptosis [45, 46]. The signal transduction pathways involved include the mitogen-activated protein kinase (MAPK), phosphatidylinositol 3′kinase (PI3K), and Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathways [47]. These intercellular signaling pathways play an important role in the development and maintenance of various cells including the interstitial cells of Cajal, mast cells, melanocytes, and hematopoietic stem cells [15, 48, 49].

3. Mutations as Drivers of Tumorigenesis in GISTs

Primary mutations in KIT or PDGFRA are a driving force for tumorigenesis and are identified prior to exposure to a tyrosine kinase inhibitor, while secondary mutations develop during targeted treatment with a tyrosine kinase inhibitor and account for acquired inhibitor resistance. KIT or PDGFRA mutations may affect either the regulatory domain (EC or JM domains) or the enzymatic domain (TK1 and TK2) of the tyrosine kinase receptor [50]. Regardless of either a primary or secondary mutation, KIT and PDGFRA mutations seen within GISTs activate receptor tyrosine kinases, leading to constitutive phosphorylation and the subsequent continued activation of the downstream intercellular signaling cascade.

The oncogenic role of mutational activation of KIT or PDGFRA kinases has been supported by familial GIST syndromes and animal studies. Familial GIST syndromes may arise from germline mutations in exon 8, exon 11, exon 13, and exon 17 of KIT and in exon 12 of PDGFRA [27, 28, 51–57]. All of these syndromes have a high penetrance with nearly every effected family member developing GISTs that are typically multiple [26, 28, 51, 52, 55, 57, 58], while other clinical findings appear to be dependent on the domain mutated. For example, mastocytosis, urticaria pigmentosa, and diffuse hyperplasia of ICC with progression to distinct GISTs have been associated with mutations involving the JM domain of KIT [25, 27], while mutations that affect the kinase domain essentially lack mastocytosis and urticaria pigmentosa [28–30]. Transgenic mouse models have been developed with “knock-in” KIT mutations at either exon 11 or exon 13 wherein the mice develop ICC hyperplasia and GISTs [59, 60]. These are similar to the mutations identified in human sporadic and familial GISTs and supports that KIT activation is central to the development of GISTs.

4. Genotype-Phenotype Correlations

Some important genotype-phenotype correlations have been identified in GISTs, not only pertaining to clinical behavior but also to the expected morphology and anatomic site of involvement for a given mutation. As mentioned previously, up to 80% of sporadic GISTs have mutations involving KIT [1–3, 6, 23] with the majority (approximately 75%) involving exon 11 of the KIT JM domain [44, 61–63] (Figure 1). The mutations cluster at either the 3′ or 5′ end of the exon. Mutations at the 5′ end most frequently include internal deletions [2, 64–68] and single nucleotide substitutions [2, 64–68], while duplications most commonly involve the 3′ end [69]. Although less common, internal tandem duplication mutations have been identified at the 3′ end of exon 11; clinically, these patients typically have gastric GISTs that follow an indolent course [68]. In comparison, an aggressive clinical course with a higher risk of recurrence and shorter survival has been noted in patients whose GISTs harbor deletions involving exon 11 [70–72]. This deletion has been shown to be an independent adverse prognostic factor [71] and when compared with GISTs that have other exon 11 mutations or are wild type, a poor disease-free survival has been associated with exon 11 deletions that specifically involve codon 557 and 558 [73–75]. The second most common KIT mutation site has been identified within exon 9 (distal extracellular domain);
in this site, duplications are most commonly found [6]. Exon 9 mutations have been identified in roughly 10%–15% of sporadic GISTs and patients whose GISTs harbor this mutation commonly have small bowel involvement and a more clinically aggressive neoplasm [68, 75]. Mutations in exons 13 and 17 affect the tyrosine kinase domain and are seen in less than 5% of sporadic GISTs [6, 76]. Mutations involving these sites typically yield a spindle cell morphology and more frequent involvement of the small bowel than stomach [77].

Approximately 7% of GISTs harbor a mutation in PDGFRA [4, 5] with the majority being missense mutations identified in exon 18 affecting the TK2 domain [78, 79]. GISTs containing this mutation most commonly involve the stomach and have an epithelioid morphology [34, 78, 80]. PDGFRA exon 14 mutations are typically missense mutations that have been associated with epithelioid morphology, location within the stomach, and a favorable clinical course [78]. Rarely, mutations have been identified in the PDGFRA JM domain (exon 12), consisting predominately of point mutations, deletions, or deletion insertions [4, 78, 79]. In general, PDGFRA mutations are found within GISTs of the stomach and omentum, typically with epithelioid or mixed epithelioid/spindle cell morphology [34, 80–84].

5. Treatment and Emergence of Secondary Mutations

In regards to treatment, the main goal for a localized GIST is complete surgical resection with negative margins and preservation of an intact pseudocapsule. The tyrosine kinase inhibitor imatinib mesylate initially played a pivotal role in the management of metastatic or unresectable disease [7, 85–87] and is now used in the adjuvant setting following complete gross resection [8]. Imatinib is a small molecule tyrosine kinase inhibitor whose structure mimics ATP and binds competitively to the intracellular portion of KIT, inhibiting signaling. This molecule also targets PDGFRA. The clinical response to imatinib has been shown to be correlative with the particular KIT or PDGFRA mutation present. GISTs with exon 11 KIT mutations have shown the best imatinib response rates (up to 80% of patients with advanced disease either had partial response or achieved stable disease), while tumours with no KIT mutation or those with a PDGFRA D842V mutation were less likely to have a favorable or a sustained response to imatinib [3, 88]. Other studies have suggested that patients with exon 9 KIT mutations may benefit from the use of higher dose imatinib [89, 90].

Most GIST patients will develop resistance to imatinib after initially achieving a clinical response. This resistance
is typically via secondary mutations that involve the kinase domain of KIT with these additional mutations found on the same allele as the primary mutation [91–94]. Some of these secondary kinase domain mutations are imatinib-resistant [91]. In these resistant tumours, the alternative kinase inhibitor sunitinib malate (SU11248 or Sutent, Pfizer, New York, NY) is being used [95–97]. This inhibitor targets several receptors including KIT, PDGFR, vascular endothelial growth factor receptors, and FLT3 and has shown clinical response in a variety of KIT and PDGFR mutations; however, the development of sunitinib resistance is also an issue. Given this resistance, novel therapeutic strategies which target different aspects of intracellular signaling are being investigated. One strategy is to diminish KIT expression by inhibition of heat-shock protein (HSP)-90, a chaperone protein that aids in protein folding to stabilize KIT from degradation. The inhibition of HSP90 prevents the stabilization of KIT and leads to its degradation [98, 99].

6. Conclusions

GISTs are clinically and histologically heterogeneous neoplasms that are driven by oncogenic KIT or PDGFR mutations. Although the majority of GISTs show an initial clinical response to imatinib, the development of resistance to this tyrosine kinase inhibitor as well as to the alternative kinase inhibitor sunitinib is problematic. Future strategies to overcome resistance will likely have to target other intracellular signaling pathways.

References

[1] S. Hirota, K. Isozaki, Y. Moriyama et al., “Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors,” Science, vol. 279, no. 5350, pp. 577–580, 1998.
[2] B. P. Rubin, S. Singer, C. Tsao et al., “KIT activation is a ubiquitous feature of gastrointestinal stromal tumors,” Cancer Research, vol. 61, no. 22, pp. 8118–8121, 2001.
[3] M. C. Heinrich, C. L. Corless, G. D. Demetri et al., “Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor,” Journal of Clinical Oncology, vol. 21, no. 23, pp. 4342–4349, 2003.
[4] M. C. Heinrich, C. L. Corless, A. Duensing et al., “PDGFR activating mutations in gastrointestinal stromal tumors,” Science, vol. 299, no. 5607, pp. 708–710, 2003.
[5] S. Hirota, A. Ohashi, T. Nishida et al., “Gain-of-function mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal tumors,” Gastroenterology, vol. 125, no. 3, pp. 660–667, 2003.
[6] M. L. Lux, B. P. Rubin, T. L. Biase et al., “KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors,” American Journal of Pathology, vol. 156, no. 3, pp. 791–795, 2000.
[7] G. D. Demetri, M. von Mehren, C. D. Blanke et al., “Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors,” New England Journal of Medicine, vol. 347, no. 7, pp. 472–480, 2002.
[8] R. P. DeMatteo, K. V. Ballman, C. R. Antonescu et al., “Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial,” Lancet, vol. 373, no. 9669, pp. 1097–1104, 2009.
[9] M. Miettinen, J. M. Monihan, M. Sarlomo-Rikala et al., “Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases,” American Journal of Surgical Pathology, vol. 23, no. 9, pp. 1109–1118, 1999.
[10] J. D. Reith, J. R. Goldblum, R. H. Lyles, and S. W. Weiss, “Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome,” Modern Pathology, vol. 13, no. 5, pp. 577–585, 2000.
[11] T. Golden and A. P. Stout, “Smooth muscle tumors of the gastrointestinal tract and retroperitoneal tissues,” Surgery Gynecology & Obstetrics, vol. 73, pp. 784–810, 1941.
[12] H. L. Evans, “Smooth muscle tumors of the gastrointestinal tract. A study of 56 cases followed for a minimum of 10 years,” Cancer, vol. 56, no. 9, pp. 2242–2250, 1985.
[13] H. D. Appelman, “Smooth muscle tumors of the gastrointestinal tract. What we know now that Stout didn’t know,” American Journal of Surgical Pathology, vol. 10, pp. 83–99, 1986.
[14] L. G. Kindblom, H. E. Remotti, F. Aldenborg, and J. M. Meis-Kindblom, “Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal,” American Journal of Pathology, vol. 152, no. 5, pp. 1259–1269, 1998.
[15] J. D. Huizinga, L. Thuneberg, M. Kluppel, J. Malyss, H. B. Mikkelsen, and A. Bernstein, “W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity,” Nature, vol. 373, no. 6512, pp. 347–349, 1995.
[16] M. Kluppel, J. D. Huizinga, J. Malyss, and A. Bernstein, “Developmental origin and Kit-dependent development of the interstitial cells of Cajal in the mammalian small intestine,” Developmental Dynamics, vol. 211, no. 1, pp. 60–71, 1998.
[17] K. M. Sanders, “A case for interstitial cells of Cajal as pacemakers and mediators of neurotransmission in the gastrointestinal tract,” Gastroenterology, vol. 111, no. 2, pp. 492–515, 1996.
[18] L. Thuneberg, “Interstitial cells of Cajal: intestinal pacemaker cells?” Advances in Anatomy, Embryology, and Cell Biology, vol. 71, pp. 1–130, 1982.
[19] J. K. Chan, “Mesenchymal tumors of the gastrointestinal tract: a paradise for acronyms (STUMP, GIST, GANT, and now GIPACT), implication of c-kit in genesis, and yet another of the many emerging roles of the interstitial cell of Cajal in the pathogenesis of gastrointestinal diseases?” Advances in Anatomic Pathology, vol. 6, no. 1, pp. 19–40, 1999.
[20] J. C. F. Lee, L. Thuneberg, I. Berezin, and J. D. Huizinga, “Generation of slow waves in membrane potential is an intrinsic property of interstitial cells of Cajal,” American Journal of Physiology, vol. 277, no. 2, part 1, pp. G409–G423, 1999.
[21] J. J. Rumessen and L. Thuneberg, “Interstitial cells of Cajal in human small intestine: ultrastructural identification and organization between the main smooth muscle layers,” Gastroenterology, vol. 100, no. 5, part 1, pp. 1417–1431, 1991.
[22] M. Miettinen, M. Sarlomo-Rikala, and J. Lasota, “Gastrointestinal stromal tumors: recent advances in understanding of their biology,” Human Pathology, vol. 30, no. 10, pp. 1213–1220, 1999.
[23] C. L. Corless, L. McGreevey, A. Haley, A. Town, and M. C. Heinrich, “KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size,” American Journal of Pathology, vol. 160, no. 5, pp. 1567–1572, 2002.

[24] A. Agaimy, P. H. Wünsch, F. Hofstaedter et al., “Minute Gastric Sclerosing Stromal Tumors (GIST Tumorlets) are common in adults and frequently show c-KIT mutations,” American Journal of Surgical Pathology, vol. 31, no. 1, pp. 113–120, 2007.

[25] C. L. Corless, J. A. Fletcher, and M. C. Heinrich, “Biological of gastrointestinal stromal tumors,” Journal of Clinical Oncology, vol. 22, no. 18, pp. 3813–3825, 2004.

[26] T. Nishida, S. Hirota, M. Taniguchi et al., “Familial gastrointestinal stromal tumours with germline mutation of the KIT gene,” Nature Genetics, vol. 19, no. 4, pp. 323–324, 1998.

[27] M. Carballo, I. Roig, F. Aguilar et al., “Novel c-KIT germline mutation in a family with gastrointestinal stromal tumors and cutaneous hyperpigmentation,” American Journal of Medical Genetics, vol. 132, no. 4, pp. 361–364, 2005.

[28] F. P. Li, J. A. Fletcher, M. C. Heinrich et al., “Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred,” Journal of Clinical Oncology, vol. 23, no. 12, pp. 2735–2743, 2005.

[29] C. O’Riain, C. L. Corless, M. C. Heinrich et al., “Gastrointestinal stromal tumors: insights from a new familial GIST kindred with unusual genetic and pathologic features,” American Journal of Surgical Pathology, vol. 29, no. 12, pp. 1680–1683, 2005.

[30] K. Hartmann, E. Wardelmann, Y. Ma et al., “Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis,” Gastroenterology, vol. 129, no. 3, pp. 1042–1046, 2005.

[31] N. P. Agaram, G. C. Wong, T. Guo et al., “Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors,” Genes Chromosomes and Cancer, vol. 47, no. 10, pp. 853–859, 2008.

[32] C. D. Mol, D. R. Dougan, T. R. Schneider et al., “Structural basis for the autoinhibition and STI-571 inhibition of c-KIT tyrosine kinase,” Journal of Biological Chemistry, vol. 279, no. 30, pp. 31655–31663, 2004.

[33] T. Pawson, “Regulation and targets of receptor tyrosine kinases,” European Journal of Cancer, vol. 38, pp. S3–S10, 2002.

[34] C. D. Mol, D. R. Dougan, T. R. Schneider et al., “Structural basis for the autoinhibition and STI-571 inhibition of c-KIT tyrosine kinase,” Journal of Biological Chemistry, vol. 279, no. 30, pp. 31655–31663, 2004.

[35] L. Rönnstrand, “Signal transduction via the stem cell factor receptor/c-KIT,” Cellular and Molecular Life Sciences, vol. 61, no. 19, pp. 2535–2548, 2004.

[36] P. Blume-Jensen, L. Claesson-Welsh, A. Siegbahn, K. M. Zsebo, and B. C. H. Westermark Heldin, “Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis,” EMBO Journal, vol. 10, no. 13, pp. 4121–4128, 1991.

[37] A. Duensing, F. Medeiros, B. McConarty et al., “Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs),” Oncogene, vol. 23, no. 22, pp. 3999–4006, 2004.

[38] S. Nishikawa, M. Kusakabe, K. Yoshinaga et al., “In utero manipulation of coat color formation by a monoclonal anti-c-kit antibody: two distinct waves of c-kit-dependency during melanocyte development,” EMBO Journal, vol. 10, no. 8, pp. 2111–2118, 1991.

[39] H. Maeyama, E. Hidaka, H. Ota et al., “Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene,” Gastroenterology, vol. 129, no. 1, pp. 210–215, 2001.

[40] K. Isozaki, B. Terris, J. Belghiti, S. Schiffmann, S. Hirota, and J. M. Vanderwinden, “Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors,” American Journal of Pathology, vol. 157, no. 5, pp. 1581–1585, 2000.

[41] A. Beghini, M. Tibiletti, G. Roveri et al., “Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa,” Cancer, vol. 92, no. 3, pp. 657–662, 2001.

[42] A. Chompret, C. Kannengiesser, M. Barrois et al., “PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor,” Gastroenterology, vol. 126, no. 1, pp. 318–321, 2004.
domain are found in a minority of human gastrointestinal stromal tumors,” Oncogene, vol. 18, no. 10, pp. 1897–1902, 1999.

[70] S. E. Steigen, T. J. Eide, B. Wasag, I. Lasota, and M. Miettinen, “Mutations in gastrointestinal stromal tumors—a population-based study from northern Norway,” APMIS, vol. 115, no. 4, pp. 289–298, 2007.

[71] J. Andersson, P. Bümming, J. M. Meis-Kindblom et al., “Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis,” Gastroenterology, vol. 130, no. 6, pp. 1573–1581, 2006.

[72] S. Cho, Y. Kitadai, S. Yoshiha et al., “Deletion of the KIT gene is associated with liver metastasis and poor prognosis in patients with gastrointestinal stromal tumor in the stomach,” International Journal of Oncology, vol. 28, no. 6, pp. 1361–1367, 2006.

[73] E. Wardelmann, I. Losen, V. Hans et al., “Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors,” International Journal of Cancer, vol. 106, no. 6, pp. 887–895, 2003.

[74] J. Martin, A. Poveda, A. Llombart-Bosch et al., “Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS),” Journal of Clinical Oncology, vol. 23, no. 25, pp. 6190–6198, 2005.

[75] R. P. DeMatteo, J. S. Gold, L. Saran et al., “Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST),” Cancer, vol. 112, no. 3, pp. 608–615, 2008.

[76] J. Lasota, A. Wozniak, M. Sarlomo-Rikala et al., “Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors: a study of 200 cases,” American Journal of Pathology, vol. 157, no. 4, pp. 1091–1095, 2000.

[77] J. Lasota, C. L. Corless, M. C. Heinrich et al., “Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases,” Modern Pathology, vol. 21, no. 4, pp. 476–484, 2008.

[78] J. Lasota, A. Dansonka-Mieszkowska, L. H. Sobin, and M. Miettinen, “A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential,” Laboratory Investigation, vol. 84, no. 7, pp. 874–883, 2004.

[79] C. L. Corless, A. Schroeder, D. Griffith et al., “PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib,” Journal of Clinical Oncology, vol. 23, no. 23, pp. 5357–5364, 2005.

[80] E. Wardelmann, A. Hrychyk, S. Merkelbach-Bruse et al., “Association of platelet-derived growth factor receptor α mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors,” Journal of Molecular Diagnostics, vol. 6, no. 3, pp. 197–204, 2004.

[81] J. Lasota, A. Dansonka-Mieszkowska, T. Stachura et al., “Gastrointestinal stromal tumors with internal tandem duplications in 3′ ends of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course,” Modern Pathology, vol. 16, no. 12, pp. 1257–1264, 2003.
Pathology Research International

genetic and histologic analysis of 60 cases of gastric gastrointestinal stromal tumors,” *Annals of Diagnostic Pathology*, vol. 11, no. 1, pp. 27–33, 2007.

[83] R. Penzel, S. Aulmann, M. Mook, M. Schwarzbach, R. J. Rieker, and G. Mechtensheimer, “The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated,” *Journal of Clinical Pathology*, vol. 58, no. 6, pp. 634–639, 2005.

[84] S. Sakurai, T. Hasegawa, Y. Sakuma et al., “Myxoid epithelioid gastrointestinal stromal tumor (GIST) with mast cell infiltrations: a subtype of GIST with mutations of platelet-derived growth factor receptor alpha gene,” *Human Pathology*, vol. 35, no. 10, pp. 1223–1230, 2004.

[85] C. D. Blanke, C. Rankin, G. D. Demetri et al., “Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033,” *Journal of Clinical Oncology*, vol. 26, no. 4, pp. 626–632, 2008.

[86] J. Verweij, P. G. Casali, J. Zalcberg et al., “Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial,” *Lancet*, vol. 364, no. 9440, pp. 1127–1134, 2004.

[87] C. D. Blanke, G. D. Demetri, M. von Mehren et al., “Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT,” *Journal of Clinical Oncology*, vol. 26, no. 4, pp. 620–625, 2008.

[88] M. Debiec-Rychter, H. Dumez, I. Judson et al., “Use of c-KIT/PDGFRα mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group,” *European Journal of Cancer*, vol. 40, no. 5, pp. 689–695, 2004.

[89] M. Debiec-Rychter, R. Sciot, A. Le Cesne et al., “KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours,” *European Journal of Cancer*, vol. 42, no. 8, pp. 1093–1103, 2006.

[90] M. C. Heinrich, K. Owzar, C. L. Corless et al., “Correlation of kinase genotype and clinical outcome in the North American intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by cancer and leukemia group B and southwest oncology group,” *Journal of Clinical Oncology*, vol. 26, no. 33, pp. 5360–5367, 2008.

[91] M. C. Heinrich, C. L. Corless, C. D. Blanke et al., “Molecular correlates of imatinib resistance in gastrointestinal stromal tumors,” *Journal of Clinical Oncology*, vol. 24, no. 29, pp. 4764–4774, 2006.

[92] G. D. Demetri, A. T. van Oosterom, C. R. Garrett et al., “Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial,” *Lancet*, vol. 368, no. 9544, pp. 1329–1338, 2006.

[93] S. Faivre, C. Delbaldo, K. Vera et al., “Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer,” *Journal of Clinical Oncology*, vol. 24, no. 1, pp. 25–35, 2006.

[94] H. Joensuu, “Second line therapies for the treatment of gastrointestinal stromal tumor,” *Current Opinion in Oncology*, vol. 19, no. 4, pp. 353–358, 2007.

[95] S. Faivre, C. Delbaldo, K. Vera et al., “Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer,” *Journal of Clinical Oncology*, vol. 24, no. 1, pp. 25–35, 2006.

[96] S. Faivre, C. Delbaldo, K. Vera et al., “Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer,” *Journal of Clinical Oncology*, vol. 24, no. 1, pp. 25–35, 2006.

[97] S. Bauer, L. K. Yu, G. D. Demetri, and J. A. Fletcher, “Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor,” *Cancer Research*, vol. 66, no. 18, pp. 9153–9161, 2006.